Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00650546
Other study ID # DK61737
Secondary ID U01DK061737
Status Completed
Phase Phase 2/Phase 3
First received March 28, 2008
Last updated May 9, 2013
Start date August 2006
Est. completion date August 2010

Study information

Verified date May 2013
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

We hypothesize that exenatide (Byetta), a GLP-1 agonist administered subcutaneously for 24-28 weeks improves liver histology in diabetic patients with biopsy-proven NASH.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date August 2010
Est. primary completion date August 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Well documented NASH based on clinical and histological criteria. Liver biopsy must have been obtained within 12-months prior to initiation of the study.

- Subjects must have known diabetes (either diet controlled or only on Metformin or sulfonylureas such as glyburide or glipizide).

- Subjects must be 18 year or older.

Exclusion Criteria:

- Co-existing etiologies for chronic liver disease (hepatitis B or C, autoimmune or hemochromatosis, etc.).

- Clinical or histological evidence of cirrhosis.

- Alanine aminotransferase or aspartate aminotransferase > 300 IU/L.

- Uncontrolled diabetes (hemoglobin A1C greater than or equal to 9%).

- Insulin or TZD dependant DM.

- Known human immunodeficiency virus infection.

- Current or history of significant alcohol consumption within past 5 years. Significant alcohol consumption is defined as >20 grm/day in females and >30 grms/day in males or if alcohol consumption cannot satisfactorily be quantified.

- Serum creatinine of greater than or equal to 2 mg/dl.

- Active, serious medical disease (cardiac, renal, pulmonary, dermatologic, psychiatric illness) with likely life expectancy less 5 years.

- Current or previous malignancy with expected life expectancy less than 5-years (other than basal cell cancer of the skin).

- Use of drugs historically associated with NASH.

- Histological evidence of malignancy, 4+ iron deposition, or any other type of liver disease.

- Active substance abuse, such as alcohol,inhaled or injection drugs with the previous one year.

- Known intolerance or allergy to exenatide (Byetta).

- History of neuroglycopenia.

- Women of childbearing potential must have had a negative pregnancy test prior to starting the study and should be willing to avoid pregnancy during the study period.

- Women must not be nursing.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Exenatide
5 mcg twice a day titrated to 10 mcg twice a day

Locations

Country Name City State
United States Indiana University Indianapolis Indiana
United States Kansas City VA Medical Center Kansas City Missouri
United States Fort Sam Houston San Antonio Texas

Sponsors (2)

Lead Sponsor Collaborator
Indiana University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

References & Publications (10)

Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005 Jul;129(1):113-21. — View Citation

Chen YE, Drucker DJ. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem. 1997 Feb 14;272(7):4108-15. — View Citation

Eng J, Andrews PC, Kleinman WA, Singh L, Raufman JP. Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. J Biol Chem. 1990 Nov 25;265(33):20259-62. — View Citation

Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992 Apr 15;267(11):7402-5. — View Citation

Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia. 1999 Jan;42(1):45-50. — View Citation

Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003 Jul;88(7):3082-9. — View Citation

Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003 Oct;38(4):1008-17. — View Citation

Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004 Jan;39(1):188-96. — View Citation

Shadid S, Jensen MD. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol. 2003 Sep;1(5):384-7. — View Citation

Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004 Mar;2(3):262-5. Erratum in: Clin Gastroenterol Hepatol. 2004 Jun;2(6):522. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in hepatic histology after 24 weeks of treatment as determined by liver biopsies pre and post-treatment 24-28 weeks Yes
Secondary Changes in anthropometric measures such as weight, BMI, WHR 24-28 weeks Yes
Secondary Change in NAS from baseline to post-treatment 24-28 weeks Yes
Secondary Changes in fibrosis, steatosis, lobular inflammation, cellular ballooning and other specific changes from the histologic scoring from baseline to post-treatment 24-28 weeks Yes
Secondary Changes in serum aminotransferase levels 24-28 weeks Yes
Secondary Changes in selected cytokines and adipokine levels 24-28 weeks Yes
Secondary Changes in insulin resistance as measure by HOMA-IR 24-28 weeks Yes
Secondary Changes in systemic lipid peroxidation and malondialdehyde 24-28 weeks Yes
See also
  Status Clinical Trial Phase
Withdrawn NCT06138327 - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria Phase 1
Completed NCT01045499 - LAGB as a Treatment for Morbid Obesity in Adolescents N/A
Completed NCT03674476 - An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function Phase 1
Not yet recruiting NCT05495139 - Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease N/A
Completed NCT04988204 - Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease N/A
Recruiting NCT04369521 - Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease N/A
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3
Enrolling by invitation NCT00983463 - Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting NCT00658164 - Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Phase 3
Recruiting NCT02148471 - Fatty Acids, Genes and Microbiota in Fatty Liver N/A
Completed NCT06441409 - Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease N/A
Completed NCT03656744 - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Phase 2
Not yet recruiting NCT01735799 - THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS N/A
Completed NCT01446276 - Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease N/A
Completed NCT00930384 - A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis N/A
Recruiting NCT02469272 - Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study Phase 1
Completed NCT02132780 - Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease N/A
Terminated NCT01355575 - Rifaximin in Fatty Liver Disease Phase 4
Completed NCT01399645 - Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes Phase 2
Completed NCT01210989 - Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis N/A